Literature DB >> 7780963

Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression.

D J Easty1, B A Guthrie, K Maung, C J Farr, R A Lindberg, R J Toso, M Herlyn, D C Bennett.   

Abstract

Epithelial cell kinase (ECK) is a receptor protein tyrosine kinase, the role of which in melanoma biology is unclear. Here we studied the role of ECK during melanoma progression. ECK mRNA was overexpressed in virtually all melanoma lines tested, and levels were significantly higher in cell lines from distant metastases than primary melanomas; melanocytes were negative. Gene amplification was not detected in melanomas. Levels of ECK protein corresponded well with mRNA levels. B61 or LERK-1, recently identified as an ECK ligand, stimulated the growth of ECK-expressing melanoma cell lines, its first identified biological activity. Melanoma chemotaxis and chemoinvasion were not affected by B61. Growth of normal melanocytes was not affected. mRNA for B61 was detected in both melanoma cell lines and normal melanocytes. B61 was also identified by Western blotting and ECK binding activity with the use of a BIAcore binding assay in melanoma cell-conditioned media. These results suggest that B61 is an autocrine growth factor for melanomas but not normal melanocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7780963

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  A role for epha2 in cell migration and refractive organization of the ocular lens.

Authors:  Yanrong Shi; Alicia De Maria; Thomas Bennett; Alan Shiels; Steven Bassnett
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-01       Impact factor: 4.799

2.  Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis.

Authors:  R Holm; S Knopp; Z Suo; C Tropè; J M Nesland
Journal:  J Clin Pathol       Date:  2006-12-08       Impact factor: 3.411

3.  Purification of a ligand for the EPH-like receptor HEK using a biosensor-based affinity detection approach.

Authors:  M Lackmann; T Bucci; R J Mann; L A Kravets; E Viney; F Smith; R L Moritz; W Carter; R J Simpson; N A Nicola; K Mackwell; E C Nice; A F Wilks; A W Boyd
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 4.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma.

Authors:  H Iida; M Honda; H F Kawai; T Yamashita; Y Shirota; B-C Wang; H Miao; S Kaneko
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 6.  Ephs and ephrins in cancer: ephrin-A1 signalling.

Authors:  Amanda Beauchamp; Waldemar Debinski
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

7.  Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter.

Authors:  S Carreira; T J Dexter; U Yavuzer; D J Easty; C R Goding
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Authors:  Philip D Dunne; Sonali Dasgupta; Patrick G Johnston; Sandra Van Schaeybroeck; Jaine K Blayney; Darragh G McArt; Keara L Redmond; Jessica-Anne Weir; Conor A Bradley; Takehiko Sasazuki; Senji Shirasawa; Tingting Wang; Supriya Srivastava; Chee Wee Ong; Ken Arthur; Manuel Salto-Tellez; Richard H Wilson
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

9.  EphA2 is an essential mediator of UV radiation-induced apoptosis.

Authors:  Guoqi Zhang; Ching-Ni Njauw; Jong Min Park; Chie Naruse; Masahide Asano; Hensin Tsao
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

10.  EphA2 as a promoter of melanoma tumorigenicity.

Authors:  Naira V Margaryan; Luigi Strizzi; Daniel E Abbott; Elisabeth A Seftor; M Sambasiva Rao; Mary J C Hendrix; Angela R Hess
Journal:  Cancer Biol Ther       Date:  2009-02-21       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.